Crinetics Pharmaceuticals (CRNX) Times Interest Earned (2017)
Crinetics Pharmaceuticals' quarterly Times Interest Earned came in at -$2501.0 in Q4 2017, down 110.7% quarter-over-quarter from -$1187.0 in Q3 2017.
Crinetics Pharmaceuticals has reported Times Interest Earned for 1 years, with the latest figure at -$2501.0 in Q4 2017.
- For the quarter ending Q4 2017, Times Interest Earned changed N/A year-over-year to -$2501.0; the trailing twelve-month figure through Sep 2018 stood at -$21780.0 (changed N/A YoY), and the FY2017 full-year result was -$1140.9, down 107.64% from the prior year.
- Times Interest Earned for Q4 2017 stood at -$2501.0, down from -$1187.0 in the prior quarter.
- The five-year high for Times Interest Earned was -$547.67 in Q2 2017, with the low at -$2501.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -2,501.00 |
| Sep 30, 2017 | -1,187.00 |
| Jun 30, 2017 | -547.67 |